Company intelligence / Profile preview

Trigemina, Inc.

Mountain View, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Trigemina’s lead program, TI‑001—an intranasal oxytocin formulation—showed positive results in a Phase IIa clinical trial for chronic daily headache, demonstrating significant reduction in pain with robust clinical signals. Dose and formulation optimization were ongoing at last report. The company also developed TI‑002 as an alternative to opiates for pain management but this program remained preclinical or pending further development.

Therapeutic areas: Neurology
Modalities: Synthetic peptidesIntranasal oxytocin formulations
Industry: Biotech

Drug pipeline

1 asset

oxytocin

Phase 2

Indications: Migraine, Craniofacial pain

Partnerships

MedVadis Research Corporation (collaborator on clinical trials)

Beyond the preview

Go deeper on Trigemina, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trigemina, Inc..

Explore the full profile